Industries > Pharma > Pharmaceutical Contract Manufacturing Market Report 2022-2032

Pharmaceutical Contract Manufacturing Market Report 2022-2032

Forecasts by Services (Pharmaceutical Manufacturing Services (Pharmaceutical API Manufacturing Services, Pharmaceutical FDF Manufacturing Services), Drug Development Services, Biologics Contract Manufacturing Services (Biologics API Manufacturing Services, Biologics FDF Manufacturing Services)), by End-user (Big Pharmaceutical Companies, Small & Medium-Sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 13 April 2022
PAGES: 441
PRODUCT CODE: PHA1157
SUBMARKET: Contract Services

Clear
WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1157 Categories: , Tags: , , ,

Investments in Advanced Manufacturing Technologies by CDMOs
In the last few decades, CDMOs have steadily established expertise and facilities to manufacture drugs at full scale. They have incorporated various methods for manufacturing drugs at the lowest possible operational cost. An increasing number of contract manufacturers are investing in continuous manufacturing methods as well to conventions in batch processing methods. Due to the availability of advanced technology, the major companies are planning to provide CDMO services for companies seeking technology development, processing and production services.

Also, to spur growth, the CDMO industry is taking on capital projects and investing in new technologies to share risks with manufacturers, in response to the high capacity utilization rates. As indicated by the higher utilization rates, they are also hiring more personnel. The manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) requires complex manufacturing processes; advanced synthesis and formulation expertise; and special protective equipment, manufacturing sites, production processes, and management systems. Such strategic expansions, investments, and acquisitions by CDMOs have helped them increase their service offerings and expand their customer base while providing significant cross-selling opportunities.

Services Analysis
Drug development services, pharmaceutical manufacturing services, and biologic manufacturing services are all subcategories of the pharmaceutical contract manufacturing sector. Pharmaceutical manufacturers’ limited financial resources, capacity constraints, the need to shorten time-to-market, complex manufacturing requirements, large investments in setting up manufacturing facilities, and the expanding pipeline have all contributed to this market segment’s dominance of pharmaceutical contract manufacturing.

Large portions of this market can be attributed to the fact that pharmaceutical manufacturers have limited resources and therefore must turn to Pharmaceutical Contract manufacturing in order to cut down on time-to-market and meet the increasingly complex manufacturing needs that have resulted from the high costs of setting up manufacturing facilities as well as the ever-expanding pipeline. On the other hand, the biologics manufacturing segment is expected to grow at the highest rate owing to the growing demand for vaccines and biosimilars.

What are the Growth Drivers for Pharmaceutical Contract Manufacturing Market?
• Patent expiry and increasing demand for generic drugs
• Increasing investments in pharmaceutical R&D
• Investments In advanced manufacturing technologies by CDMOs

What are the Market Opportunities?
• Increasing demand for biological therapies
• Growth in the nuclear medicine sector
• Growing demand for cell and gene therapies

Discover how to stay ahead
Our 440+ page report provides 600+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Pharmaceutical Contract Manufacturing Market. See how to exploit the opportunities.

Forecasts to 2032 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), PEST Analysis, Porter’s Five Forces, SWOT Analysis, product profiles and commercial developments.

Discover sales predictions for the world market and sub-markets

By Services
• Pharmaceutical Manufacturing Services
– Pharmaceutical API Manufacturing Services
– Pharmaceutical FDF Manufacturing Services
• Drug Development Services
• Biologics contract manufacturing services
– Biologics API manufacturing services
– Biologics FDF manufacturing services

By End User
• Big Pharmaceutical Companies
• Small & Medium-Sized Pharmaceutical Companies
• Generic Pharmaceutical Companies
• Other End Users

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 14 leading national markets:

By Region

North America
• U.S.
• Canada

Europe
• Germany
• France
• UK
• Italy
• Spain
• Switzerland
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• South Korea
• Rest of Asia Pacific

LAMEA
• Brazil
• Mexico
• Rest of LAMEA

Pharmaceutical Contract Manufacturing Market Report 2022-2032
Need industry data? Please contact us today.

Leading companies and the potential for market growth
Overall world revenue for Pharmaceutical Contract Manufacturing Market will surpass $126 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Prospects for established firms and those seeking to enter the market– including company profiles for 18 of the major companies involved in the Pharmaceutical Contract Manufacturing market. Some of the companies profiled in this report include AbbVie Inc., Abnova Corporation, Boehringer Ingelheim International GmbH, Catalent, Inc., Evonik Industries AG, Fujifilm Corporation, ICON PLC, Lonza Group Ltd., Piramal Pharma Solutions, Recipharm AB, Samsung Biologics, Siegfried Holding AG, Thermo Fisher Scientific Inc., Vetter Pharma International GmbH, and WuXiAppTec among other prominent players.

How the Pharmaceutical Contract Manufacturing Market report helps you
In summary, our 440+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Pharmaceutical Contract Manufacturing Market, with forecasts for 3 services, and 4 end-users each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2032 for 4 regional and 14 key national markets– See forecasts for the Pharmaceutical Contract Manufacturing market in North America, Europe, Asia Pacific, and Rest of the World. These regional markets have been further bifurcated by countries including US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, China, India, Japan, Australia, South Korea, among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the companies involved in the Pharmaceutical Contract Manufacturing Market. Some of the company’s profiled in this report include AbbVie Inc., Abnova Corporation, Boehringer Ingelheim International GmbH, Catalent, Inc., Evonik Industries AG, Fujifilm Corporation, ICON PLC, Lonza Group Ltd., Piramal Pharma Solutions, Recipharm AB, Samsung Biologics, Siegfried Holding AG, Thermo Fisher Scientific Inc., Vetter Pharma International GmbH, and WuXiAppTec among other prominent players.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Pharmaceutical Contract Manufacturing Market and leading companies. You will find data, trends, and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Pharmaceutical Contract Manufacturing Market Report 2022-2032: Forecasts by Services (Pharmaceutical Manufacturing Services (Pharmaceutical API Manufacturing Services, Pharmaceutical FDF Manufacturing Services), Drug Development Services, Biologics Contract Manufacturing Services (Biologics API Manufacturing Services, Biologics FDF Manufacturing Services), by End-user (Big Pharmaceutical Companies, Small & Medium-Sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market Report 2022-2032


Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market Report 2022-2032


Latest Pharma news

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

READ

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

READ

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

READ

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

READ